<DOC>
	<DOCNO>NCT02851485</DOCNO>
	<brief_summary>This open-label study determine pharmacokinetics new tablet formulation GLPG1972 compare liquid solution use First-in-Human study ( GLPG1972-CL-101 ) . The impact food intake oral bioavailability GLPG1972 administer tablet also investigate study . A dose 600 mg select . The study phase I randomize open-label cross-over study three single dose treatment : A ) 600 mg GLPG1972 oral solution overnight fast , B ) 600 mg GLPG1972 oral tablet overnight fast , C ) 600 mg GLPG1972 oral tablet 30 minute high-fat high-calorie breakfast . A washout least 6 day subsequent dose day respect measurable plasma level biologically significant effect remain . There frequent assessment adverse experience post-dose . Twelve healthy male subject select accord inclusion exclusion criterion 2 subject randomize one 6 treatment sequence ( ABC , ACB , BAC , BCA , CAB , CBA )</brief_summary>
	<brief_title>Bioavailability Study With GLPG1972</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>1 . Male 18 50 year age , inclusive , day signing inform consent form ( ICF ) . 2 . A body mass index ( BMI ) 1830 kg/mÂ² , inclusive , weight least 50 kg . 3 . Judged investigator good health base upon result medical history , physical examination , vital sign , 12lead ECG , laboratory finding . 4 . Discontinuation medication ( include overthecounter and/or prescription medication , dietary supplement , nutraceuticals , vitamin and/or herbal supplement ) except occasional paracetamol ( maximum dose 2 g/day maximum 10 g/2 week ) least 2 week 5 halflives medication prior first study drug administration . In addition , subject must agree follow prohibition restriction study . 5 . Nonsmokers use nicotinecontaining product ( abstained smoking least 1 year prior screen ) . 6 . Negative urine alcohol drug screen ( amphetamine , barbiturate , benzodiazepine , cannabis , cocaine , opiates , methadone , tricyclic antidepressant , alcohol ) . 7 . Current sexually active ( and/or child wish ) male agree use adequate contraception ( see Section 4.2.4.1 ) time first dose study drug , study 12 week last study drug dose . 8 . Subjects willing consume nonvegetarian high fat high calorie breakfast . 9 . Able willing sign ICF approve IEC , prior screen evaluation 1 . Known hypersensitivity study drug ingredient significant allergic reaction drug 2 . Positive serology hepatitis B virus surface antigen ( HBsAg ) hepatitis C virus ( HCV ) history hepatitis cause exception hepatitis A . 3 . History current immunosuppressive condition 4 . Symptoms clinically significant illness 3 month initial study drug administration . 5 . Presence sequelae gastrointestinal , liver ( except Gilbert 's disease ) kidney disease condition know interfere absorption , distribution , metabolism , excretion drug . 6 . History malignancy within past 5 year ( except basal cell carcinoma skin treat evidence recurrence ) . 7 . Clinically relevant abnormality detect ECG . A first degree heart block sinus arrhythmia consider significant abnormality . 8 . Clinically relevant abnormality detect vital sign . 9 . Intolerance cow milk . 10 . Significant blood loss include blood donation ( &gt; 100 mL ) transfusion blood product within 12 week prior initial study drug administration . 11 . Hemoglobin level 7.5 mmol/L . 12 . Treatment drug know welldefined potential toxicity major organ last 3 month precede initial study drug administration . 13 . Active drug alcohol abuse ( average intake 21 glass wine beer equivalent/week ) within 2 year prior initial study drug administration . 14 . Consumption large quantity coffee , tea ( &gt; 6 cup per day ) equivalent . 15 . Administration injectable drug within 30 day prior initial study drug administration .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>